Helsinn is a privately owned, self-financing pharmaceutical group with headquarters in Lugano, Switzerland and premises in Ireland and USA. The Helsinn Group has been built on the basis of a unique business model, focused on the in- and out-licensing of pharmaceuticals, with the recent additions of medical devices in therapeutic niche areas.Helsinn is an important player in Cancer Supportive CareHelsinn in-licenses early-to-late stage new chemical entities from small and big pharma companies, completes their development through the performance of preclinical and clinical studies and of chemistry, manufacturing and control (CMC) development and files and attains their market approval worldwide. The Group markets its products directly through its network of local pharmaceutical partners, selected for their deep in-market knowledge and know-how, whom Helsinn assists and supports with a full range of product and scientific management services, including commercial, regulatory, financial, legal and medical marketing advice.The active pharmaceutical ingredients and the finished dosage products are manufactured to the highest quality, safety and environmental standards, in compliance with U.S. FDA, EU EMA, Swissmedic, Japanese PMDA and PIC requirements at Helsinn’s facilities in Switzerland and Ireland, and supplied worldwide to its customers.